Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Sakamoto T, et al. Among authors: sato y. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. JAMA Netw Open. 2023. PMID: 38100106 Free PMC article.
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis.
Ikeda S, Kato T, Kenmotsu H, Ogura T, Iwasawa S, Sato Y, Harada T, Kubota K, Tokito T, Okamoto I, Furuya N, Yokoyama T, Hosokawa S, Iwasawa T, Yamanaka T, Okamoto H. Ikeda S, et al. Among authors: sato y. J Thorac Oncol. 2020 Dec;15(12):1935-1942. doi: 10.1016/j.jtho.2020.08.018. Epub 2020 Aug 25. J Thorac Oncol. 2020. PMID: 32858235 Free PMC article. Clinical Trial.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Sakai K, Tsuboi M, Kenmotsu H, Yamanaka T, Takahashi T, Goto K, Daga H, Ohira T, Ueno T, Aoki T, Nakagawa K, Yamazaki K, Hosomi Y, Kawaguchi K, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Okabe K, Yamamoto N, Nishio K. Sakai K, et al. Among authors: sato y. Cancer Sci. 2021 Jan;112(1):388-396. doi: 10.1111/cas.14730. Epub 2020 Nov 30. Cancer Sci. 2021. PMID: 33185928 Free PMC article. Clinical Trial.
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Tamiya A, Iwasawa S, Hata A, Uchida J, Fukuda Y, Hara S, Kanazu M, Hirano K, Kokubo M, Yamamoto N. Sugimoto T, et al. Among authors: sato y. Invest New Drugs. 2021 Jun;39(3):853-859. doi: 10.1007/s10637-020-01060-8. Epub 2021 Jan 6. Invest New Drugs. 2021. PMID: 33405089 Clinical Trial.
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T, Sakai K, Kenmotsu H, Yoh K, Daga H, Ohira T, Ueno T, Aoki T, Hayashi H, Yamazaki K, Hosomi Y, Chen-Yoshikawa TF, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Inokawa H, Yamamoto N, Nishio K, Tsuboi M. Takahashi T, et al. Among authors: sato y. Cancer Sci. 2022 Jan;113(1):287-296. doi: 10.1111/cas.15171. Epub 2021 Nov 7. Cancer Sci. 2022. PMID: 34689382 Free PMC article. Clinical Trial.
Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L).
Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Okamoto I, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K; members of the West Japan Oncology Group (WJOG). Tachihara M, et al. Among authors: sato y. Cancer Manag Res. 2021 Dec 14;13:9167-9173. doi: 10.2147/CMAR.S336262. eCollection 2021. Cancer Manag Res. 2021. PMID: 34934361 Free PMC article.
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.
Tamiya M, Fujikawa K, Suzuki H, Yokoyama T, Uenami T, Tamiya A, Sato Y, Saito G, Uchida J, Morita M, Hirashima T, Fukuda Y, Kanazu M, Hosoya K, Suzuki T, Ueno K, Fujimoto D, Kumagai T, Teramukai S. Tamiya M, et al. Among authors: sato y. Invest New Drugs. 2022 Apr;40(2):361-369. doi: 10.1007/s10637-021-01203-5. Epub 2022 Jan 28. Invest New Drugs. 2022. PMID: 35088212
13,916 results
You have reached the last available page of results. Please see the User Guide for more information.